ALNY Q3'26 Earnings: EPS estimate is 1.66 USD

What happened

Alnylam Pharmaceuticals is set to announce its Q3'26 results on October 29 before the market opens at 8:00 AM ET. The revenue estimate is 1.43 billion USD and the EPS estimate is 1.66 USD.

Confirmed

Global impact / market context

Earnings per share, which means profit divided by shares outstanding, is estimated at 1.66 USD. If Alnylam meets the 1.43 billion USD revenue estimate, sales would rise from the prior reported quarter, showing whether demand is growing as analysts expect.

Analyst inference

The estimates imply Alnylam would report higher revenue and EPS than in the prior quarter. Past results beat or missed estimates, so the upcoming report will show whether the company reaches the forecast profit and sales levels investors expect.

Analyst inference

What to watch

1. Alnylam is scheduled to report Q3'26 results on October 29 before the market opens at 8:00 AM ET, which is 12:00 PM UTC. Confirmed
2. Watch whether reported revenue reaches the 1.43 billion USD estimate; a miss or beat would show whether the company's sales are meeting the forecast used by investors. Proposed
3. Watch whether reported EPS reaches the 1.66 USD estimate, because profit per share affects how investors judge the company's profitability relative to the forecast. Analyst inference

Evidence

• Original source link unavailable